Peter E.Lobie

Prof. Peter E.Lobie

Centre for Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Tsinghua University, Nanshan, Shenzhen 518000, China

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMingming Wu
Mingming Wu
XZXiao Zhang
Xiao Zhang
WZWeijie Zhang
Weijie Zhang
Yi Shiou ChiouYi Shiou Chiou
Yi Shiou Chiou
WQWenchang Qian
Wenchang Qian
TZTao Zhu
Tao Zhu
Cancer cells display phenotypic equilibrium between the stem-like and differentiated states during neoplastic homeostasis. The functional and mechanistic implications of this subpopulation plasticity remain largely unknown. Herein, it is demonstrated that the breast cancer stem cell (BCSC) secretome autonomously compresses the stem cell population. Co-implantation with BCSCs decreases the tumor-initiating capacity yet increases metastasis of accompanying cancer cells, wherein DKK1 is identified as a pivotal factor secreted by BCSCs for such functions. DKK1-promotes differentiation is indispensable for disseminated tumor cell metastatic outgrowth. In contrast, DKK1 inhibitors substantially relieve the metastatic burden by restraining metastatic cells in the dormant state. DKK1 increases the expression of SLC7A11 to protect metastasizing cancer cells from lipid peroxidation and ferroptosis. Combined treatment with a ferroptosis inducer and a DKK1 inhibitor exhibits synergistic effects in diminishing metastasis. Hence, this study deciphers the contribution of CSC-regulated phenotypic plasticity in metastatic colonization and provides therapeutic approaches to limit metastatic outgrowth.

9 February 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LYLinlin Yan
Linlin Yan
MWMingming Wu
Mingming Wu
TWTianyu Wang
Tianyu Wang
HYHui Yuan
Hui Yuan
XZXiao Zhang
Xiao Zhang
TZTao Zhu
Tao Zhu
Reprogramming of energy metabolism exerts pivotal functions in cancer progression and immune surveillance. Identification of the mechanisms mediating metabolic changes in cancer may lead to improved strategies to suppress tumor growth and stimulate antitumor immunity. Here, it was observed that the secretomes of hypoxic breast cancer cells and breast cancer stem cells (BCSC) induced reprogramming of metabolic pathways, particularly glycolysis, in normoxic breast cancer cells. Screening of the BCSC secretome identified MIF as a pivotal factor potentiating glycolysis. Mechanistically, MIF increased c-MYC–mediated transcriptional upregulation of the glycolytic enzyme aldolase C by activating WNT/β-catenin signaling. Targeting MIF attenuated glycolysis and impaired xenograft growth and metastasis. MIF depletion in breast cancer cells also augmented intratumoral cytolytic CD8+ T cells and proinflammatory macrophages while decreasing regulatory T cells and tumor-associated neutrophils in the tumor microenvironment. Consequently, targeting MIF improved the therapeutic efficacy of immune checkpoint blockade in triple-negative breast cancer. Collectively, this study proposes MIF as an attractive therapeutic target to circumvent metabolic reprogramming and immunosuppression in breast cancer. Significance: MIF secreted by breast cancer stem cells induces metabolic reprogramming in bulk tumor cells and engenders an immunosuppressive microenvironment, identifying MIF targeting as a strategy to improve immunotherapy efficacy in breast cancer.

21 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
Samarth KansaraSamarth Kansara
Samarth Kansara
VPVijay Pandey
Vijay Pandey
PEPeter E.Lobie
Peter E.Lobie
Gautam SethiGautam Sethi
Gautam Sethi
MGManoj Garg
Manoj Garg
APAmit Kumar Pandey
Amit Kumar Pandey
Triple-negative breast cancer (TNBC) is one of the most lethal forms of breast cancer (BC), with a significant disease burden worldwide. Chemoresistance and lack of targeted therapeutics are major hindrances to effective treatments in the clinic and are crucial causes of a worse prognosis and high rate of relapse/recurrence in patients diagnosed with TNBC. In the last decade, long non-coding RNAs (lncRNAs) have been found to perform a pivotal role in most cellular functions. The aberrant functional expression of lncRNAs plays an ever-increasing role in the progression of diverse malignancies, including TNBC. Therefore, lncRNAs have been recently studied as predictors and modifiers of chemoresistance. Our review discusses the potential involvement of lncRNAs in drug-resistant mechanisms commonly found in TNBC and highlights various therapeutic strategies to target lncRNAs in this malignancy.

1 February 2018 in Cancer Letters
Verified
Journal Article
Closed access
NBNgoc-Linh-Chi Bui
Ngoc-Linh-Chi Bui
VPVijay Pandey
Vijay Pandey
TZTao Zhu
Tao Zhu
LMLan MA
Lan MA
Basappa BasappaBasappa Basappa
Basappa Basappa
PEPeter E.Lobie
Peter E.Lobie

3 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYuanxiong Cao
Yuanxiong Cao
JTJiayi Tan
Jiayi Tan
HZHaoran Zhao
Haoran Zhao
TDTing Deng
Ting Deng
YHYunxia Hu
Yunxia Hu
SMShaohua Ma
Shaohua Ma
Transplantation of mesenchymal stem cells (MSCs) holds promise to repair severe traumatic injuries. However, current transplantation practices limit the potential of this technique, either by losing the viable MSCs or reducing the performance of resident MSCs. Herein, we design a “bead-jet” printer, specialized for high-throughput intra-operative formulation and printing of MSCs-laden Matrigel beads. We show that high-density encapsulation of MSCs in Matrigel beads is able to augment MSC function, increasing MSC proliferation, migration, and extracellular vesicle production, compared with low-density bead or high-density bulk encapsulation of the equivalent number of MSCs. We find that the high-density MSCs-laden beads in sparse patterns demonstrate significantly improved therapeutic performance, by regenerating skeletal muscles approaching native-like cell density with reduced fibrosis, and regenerating skin with hair follicle growth and increased dermis thickness. MSC proliferation within 1-week post-transplantation and differentiation at 3 − 4 weeks post-transplantation are suggested to contribute therapy augmentation. We expect this “bead-jet” printing system to strengthen the potential of MSC transplantation.

1 August 2021 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
Yan Qin TanYan Qin Tan
Yan Qin Tan
XZXi Zhang
Xi Zhang
SZShuwei Zhang
Shuwei Zhang
TZTao Zhu
Tao Zhu
MGManoj Garg
Manoj Garg
VPVijay Pandey
Vijay Pandey